Can-Fite BioPharma American Depositary Shares
CANF
16 hedge funds and large institutions have $272K invested in Can-Fite BioPharma American Depositary Shares in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
6.25% less ownership
Funds ownership: 9.77% → 3.52% (-6.2%)
78% less capital inflows, than outflows
Capital inflows: $199K | Capital outflows: $893K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$87.7K |
| 2 |
Jane Street
New York
|
+$80.3K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$14.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.7K |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
+$7.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$871K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$10.3K |
| 3 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$7.04K |
| 4 |
Morgan Stanley
New York
|
-$4.9K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$78 |
CANF Hedge Fund Activity: Q4 2025 in Review
16 of the 8,302 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2025, worth a combined $272K — down 71% from $954K a quarter earlier.
Fund positioning in CANF was balanced in Q4 2025: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was RhumbLine Advisers, adding an estimated $87.7K. The largest seller was Sabby Management, exiting entirely with an estimated $871K sold.
- 16 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $272K of Can-Fite BioPharma American Depositary Shares stock for Q4 2025, down 71% quarter-over-quarter.
- 3 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2025 and 3 closed out, a net change of 0 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2025 was RhumbLine Advisers, an estimated $87.7K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q4 2025 was Sabby Management, an estimated $871K sold.
Based on aggregated 13F filings for Q4 2025.